{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:30:04Z","timestamp":1793039404408,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2020LZL019"],"award-info":[{"award-number":["ZR2020LZL019"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172865"],"award-info":[{"award-number":["82172865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.cllc.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:18:01Z","timestamp":1739416681000},"page":"221-227.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy"],"prefix":"10.1016","volume":"26","author":[{"given":"Junyi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Butuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2231-6642","authenticated-orcid":false,"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2025.02.006_bib0001","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.cllc.2025.02.006_bib0002","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: a systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"21","key":"10.1016\/j.cllc.2025.02.006_bib0003","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013Small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.cllc.2025.02.006_bib0004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.cllc.2025.02.006_bib0005","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2025.02.006_bib0006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.cllc.2025.02.006_bib0007","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.cllc.2025.02.006_bib0008","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of Pembrolizumab after stereotactic body radiotherapy vs Pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.02.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001001","article-title":"Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial","volume":"8","author":"Welsh","year":"2020","journal-title":"J ImmunoTher Cancer"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.006_bib0010","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.02.006_bib0011","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.006_bib0012","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.cllc.2025.02.006_bib0013","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"issue":"2","key":"10.1016\/j.cllc.2025.02.006_bib0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.cllc.2025.02.006_bib0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ijrobp.2015.08.012","article-title":"Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer: results of a multicenter phase 2 study from PPRA-RTOG, China","volume":"93","author":"Su","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"24","key":"10.1016\/j.cllc.2025.02.006_bib0016","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.3390\/cancers13246193","article-title":"Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.cllc.2025.02.006_bib0017","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of radiation dose to the host immune system on tumor control and survival for stage III non-small cell lung cancer treated with definitive radiation therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2025.02.006_bib0018","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","author":"Breen","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.02.006_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2021.06.020","article-title":"Impact of effective dose to immune cells (EDIC) on lymphocyte nadir and survival in limited-stage SCLC","volume":"162","author":"Yu","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.02.006_bib0020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","article-title":"The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy","volume":"146","author":"Xu","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.02.006_bib0021","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2021.01.034","article-title":"Risk and impact of radiation related lymphopenia in lung cancer: a systematic review and meta-analysis","volume":"157","author":"Upadhyay","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.02.006_bib0022","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","article-title":"A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors","volume":"123","author":"Venkatesulu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.006_bib0023","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.adro.2020.03.021","article-title":"Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma","volume":"5","author":"So","year":"2020","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2025.02.006_bib0024","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","article-title":"Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer","volume":"105","author":"Cho","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.cllc.2025.02.006_bib0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3390\/cancers13030457","article-title":"Radiotherapy-immunotherapy combination: how will we bridge the gap between pre-clinical promise and effective clinical delivery?","volume":"13","author":"Romano","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cllc.2025.02.006_bib0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.lungcan.2021.01.022","article-title":"Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy","volume":"154","author":"Friedes","year":"2021","journal-title":"Lung Cancer"},{"issue":"4991","key":"10.1016\/j.cllc.2025.02.006_bib0027","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(01)38951-1","article-title":"Experimental studies with small doses of x rays","volume":"193","author":"Russ","year":"1919","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.cllc.2025.02.006_bib0028","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/CM9.0000000000002217","article-title":"Organ-specific efficacy in advanced non-small cell lung cancer patients treated with first-line single-agent immune checkpoint inhibitors","volume":"135","author":"Deng","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"12","key":"10.1016\/j.cllc.2025.02.006_bib0029","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.3390\/ijms23126832","article-title":"Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications","volume":"23","author":"Del Conte","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cllc.2025.02.006_bib0030","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.radonc.2022.05.002","article-title":"Causal relation between heart irradiation and survival of lung cancer patients after radiotherapy","volume":"172","author":"Brink","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.cllc.2025.02.006_bib0031","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2018.10.029","article-title":"Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer","volume":"133","author":"Xue","year":"2019","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.02.006_bib0032","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijrobp.2018.05.052","article-title":"Residual setup errors towards the heart after image guidance linked with poorer survival in lung cancer patients: do we need stricter IGRT protocols?","volume":"102","author":"Johnson-Hart","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.cllc.2025.02.006_bib0033","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2020.12.019","article-title":"Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy","volume":"156","author":"Kim","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:47:22Z","timestamp":1762548442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1525730425000361"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Radiation Dose to Immune Cells in Stage IV Non-Small Cell Lung Cancer in the Era of Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}